



The role of allogeneic stem-cell transplant in myelofibrosis
in the era of JAK inhibitors: a case-based review
Mario Tiribelli 1 ● Francesca Palandri2 ● Emanuela Sant’Antonio3 ● Massimo Breccia4 ● Massimiliano Bonifacio5
Received: 30 May 2019 / Revised: 29 July 2019 / Accepted: 2 August 2019
© The Author(s), under exclusive licence to Springer Nature Limited 2019. This article is published with open access
Abstract
Allogeneic hematopoietic stem-cell transplantation (HSCT) is, at present, the only potentially curative therapy for
myelofibrosis (MF). Despite many improvements, outcomes of HSCT are still burdened by substantial morbidity and high
transplant-related mortality. Allogeneic transplant is generally considered in intermediate-2 and high-risk patients aged <70
years, but the optimal selection of patients and timing of the procedure remains under debate, as does as the role of JAK
inhibitors in candidates for HSCT. Starting from a real-life clinical case scenario, herein we examine some of the crucial
issues of HSCT for MF in light of recent refinements on MF risk stratification, data on the use of ruxolitinib before and after
transplant and findings on the impact of different conditioning regimens and donor selection.
Introduction
Myelofibrosis (MF) is a myeloproliferative neoplasm that
may present as primary (PMF) or as the evolution of a
previous polycythemia vera (PV) or essential thrombo-
cythemia (ET), in which case it is referred to as secondary
myelofibrosis (SMF) [1]. MF is a clonal stem-cell process
that gives rise to bone marrow fibrosis, extramedullary
hematopoiesis, frequent splenomegaly and anemia, con-
stitutional symptoms, and cachexia; its clinical course is
defined by a tendency toward leukemic progression and
shortened survival [2].
Patients with intermediate- or high-risk disease are can-
didates for therapy that may include conventional drugs
(e.g., hydroxyurea), transfusions, splenectomy or, more
recently, JAK inhibitors such as ruxolitinib. These treat-
ments have the major aim of improving both symptoms and
overall survival, as well as quality of life [2]. However,
allogeneic hematopoietic stem-cell transplantation (HSCT)
currently remains the only therapy that may modify the
natural history of MF [3]. As a consequence, the number of
allogeneic HSCTs performed for MF has been increasing
over the past years, despite the approval of JAK inhibitors
[2, 4]. Notwithstanding, HSCT is associated with high
treatment-related morbidity and mortality, particularly in
older adults, where the risk of the procedure may outweigh
the risk of disease. Moreover, HSCT requires both good
performance status and a suitable stem-cell donor [4]: in
recent years, the number of patients undergoing transplants
using matched unrelated donors (MUD) and employing
reduced-intensity conditioning (RIC) regimens has
increased significantly, representing more than two-thirds of
all HSCTs [5]. Nevertheless, rates of mortality and relapse
related to transplant remain high, thus posing a major
challenge to hematologists. Herein, a case-based review is
used as the basis to briefly review the role of HSCT in MF
in the current era of JAK inhibitors.
Case presentation
A 51-year-old woman was admitted to the emergency
department in December 2003 for balance disorder
and was found to have extreme thrombocytosis (platelets
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2667 × 103/µL) and mild leukocytosis (WBC 19.0 × 103/µL
with 89% neutrophils). Bone marrow biopsy and aspirate
were consistent with ET, karyotype was 46XX, and mole-
cular analysis was negative for BCR/ABL. The patient was
treated with hydroxyurea with partial hematologic remis-
sion; in 2004 anagrelide therapy was started, with complete
normalization of platelet counts and without significant
toxicity.
Starting August 2011 progressive thrombocytopenia and
splenomegaly developed, and in November 2013 a bone
marrow biopsy documented progression to SMF. The
patient was negative for the JAK2 V617F mutation, and the
IPSS score was 1 (circulating blasts 4%), corresponding to
an intermediate-1 risk group. A few months later, the
decision was made to enroll the patient in a protocol testing
ruxolitinib in MF (JUMP trial, NCT01493414). Complete
blood count (CBC) was: Hb 10.9 g/dL, platelets 92 × 103/
µL, WBC 19.0 × 103/µL (neutrophils 72%, blasts 3%);
spleen was palpable at 7 cm below the left costal margin
(LCM). Electrocardiogram revealed a previous anteroseptal
myocardial infarction and first-degree atrioventricular
block. Ruxolitinib was started at 5 mg BID on April 2014;
at the time of initiation, the patient had no relevant symp-
toms (DIPSS score of 1 due to circulating blasts). After
6 months of therapy, spleen size was unchanged, and the
dose of ruxolitinib was increased to 10 mg BID, without
any significant reduction in spleen size at any of the sub-
sequent evaluations. However, the ruxolitinib dose was not
further escalated due to platelet counts <100 × 103/µL.
In October 2016, 2.5 years after starting ruxolitinib, at
which time the patient was 65 years old, the spleen was
palpable at 9 cm below LCM and CBC was as follows: Hb
9.8 g/dL, platelets 89 × 103/µL, WBC 34.9 × 103/µL (neu-
trophils 48%, blasts 8%). Bone marrow biopsy revealed
grade 3 fibrosis. The DIPSS score was 4 and the risk group
was intermediate-2. The patient exited the formal protocol,
but continued ruxolitinib therapy at 10 mg BID with the
addition of hydroxyurea 1 g/day due to leukocytosis and
increasing splenomegaly.
In August 2017, at the age of 66, CBC was substantially
unchanged and spleen size had further increased; DIPSS
score was 5 (high risk). Calreticulin (CALR) gene analysis
revealed a type 2 mutation. An echocardiogram and pul-
monary function tests were performed, and the patient was
evaluated by the allogeneic HSCT team in October 2017.
Due to the lack of a sibling donor, a search for a MUD
started in November 2017, while the patient continued
treatment with ruxolitinib and hydroxyurea. The patient
began transfusions with red cells in November 2017, and in
February 2018 she experienced repeated episodes of con-
gestive heart failure requiring cardiovascular therapy. In
March 2018, bone marrow biopsy showed grade 3 fibrosis
and osteosclerosis. The patient now required continuous
transfusion with 4 units of red cells per month; spleen size
was stable, but abdominal ultrasound revealed portal and
splenic vein thrombosis that prompted introduction of
heparin therapy.
In April 2018, an 8/8 HLA-MUD was identified. Pre-
transplant comorbidity index (HTC-CI) score according to
Sorror [6] was 5 (congestive heart failure, reduced DLCO,
depression). In June 2018, the patient underwent allogeneic
HSCT with PB-derived stem cells; harvest consisted of
5.8 × 106/kg CD34+ cells and 52.2 × 107/kg CD3+ cells.
The dose of ruxolitinib was quickly tapered starting from
7 days before and stopped the day before the start of the
conditioning regimen. The non-myeloablative conditioning
(MAC) regimen consisted of fludarabine 30 mg/m2 on day
−8 to day −3 and thiotepa 6 mg/kg for 2 doses on days −4
and −3, while prophylaxis for graft-versus-host disease
(GvHD) included cyclosporine A, short-course methotrex-
ate, and ATG thymoglobulin (3.5 mg/kg for two doses).
Prophylaxis for Epstein Barr virus consisted of rituximab
200 mg/m2 on day −2.
The posttransplant period was characterized by suspected
veno-occlusive disease, with jaundice, weight gain, and
abdominal discomfort, which was treated with defibrotide
for 18 days. The patient did not develop acute GvHD.
Neutrophil recovery (ANC > 1000) was documented on day
+17, while platelet recovery (PLT > 30,000/mmc) was
attained only on day +90; due to poor graft function, GCSF
and transfusions were needed in the months following SCT.
Posttransplant chimerism analysis performed on peripheral
blood CD3+ cells at 1, 3, and 4 months after SCT showed
≥95% of donor cells.
At last follow up, 5 months after HSCT, the patient was
in stable conditions, with no signs or symptoms of GvHD.
The spleen was palpable at 5 cm from LCM and CBC was
as follows: Hb 8.5 g/dL, platelets 53 × 103/µL, WBC 3.6 ×
103/µL (neutrophils 60%, lymphocytes 20%, no precursor
nor blasts); transfusion of red cells is needed about once
weekly.
Discussion
The present case report allows for several observations on
management of MF in the era of JAK inhibitors, as sum-
marized in Fig. 1.
Pretransplant evaluation: prognostic scores and
considerations about use of JAK inhibitors
The mean age of patients diagnosed with MF is more than
65 years [7], and the age of the patient described herein is in
line with this affirmation. At about 8 years after initial
diagnosis of ET, progressive thrombocytopenia and
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splenomegaly were observed, and bone marrow biopsy
documented progression to SMF. The management of SMF
is almost identical to that of de novo PMF [8], despite the
biological differences between primary and secondary MF.
Initially, the patient’s DIPSS score was 1 with risk group
intermediate-1 and, accordingly, HSCT was not considered
to be a frontline therapeutic option, since it was largely
performed in younger, fit patients with higher risk disease
[9]. Moreover, while some studies have identified that
subclonal nondriver mutations (i.e., ASXL1, EZH2, IDH1/2,
and SRSF2) have an adverse effect on overall and
leukemia-free survival [10, 11], and therefore may be used
as a decisional tool for transplant (MIPPS70 [12]), this kind
of analysis was not available in clinical practice in 2013,
and the only information about the mutational status of our
patient was the negativity for JAK2 V617F. It should also
be pointed out that the prognostic impact of subclonal
mutations has been mostly studied in cases of PMF, while
its relevance in SMF has not yet been demonstrated [13].
Indeed, given the older age and likely coexistence of
medical conditions, most patients are not considered for
HSCT because of concerns regarding treatment-related
toxicity [2], and some studies have reported decreased
survival in patients older than 55 years of age [14, 15].
Based on these considerations, the patient was proposed
enrollment in a protocol for ruxolitinib treatment, due to the
presence of splenomegaly [16]. A similar approach has also
been recently recommended by a panel of experts from the
European LeukemiaNet and the Italian Society of Hema-
tology [17].
After almost 3 years on ruxolitinib at what was con-
sidered to be the maximal tolerable dose, splenomegaly
and thrombocytopenia were still evident and even con-
sidering that the patient was 66 years old, she was referred
to evaluation by an allogeneic HSCT team, since her
DIPSS score had increased to 4, corresponding to an
intermediate-2 risk group. There is some discrepancy on
the utility of DIPSS score in predicting outcomes [2].
While some studies have shown better outcomes for
patients transplanted with a lower DIPSS score [18],
patients with low-risk disease are generally not considered
for transplant because survival rates appear to be higher
with pharmacologic and supportive therapy, at least in the
pre-ruxolitinib era [2, 19]. In addition, a clear distinction
has to be made between the prognostic score related to
MF itself, and the prognostic score about transplant risk.
Prognostication about disease evolution can be made
using simple clinical variables (IPSS or DIPSS score,
[20, 21]) or considering biological characteristics such as
cytogenetic (DIPSS-plus, [22]), driver mutations
(MYSEC-PM, [23]) or the combination of driver and
subclonal mutations (MIPSS-70, [12]). It is presently
unclear which score is more accurate in defining the
indication for transplant, particularly when a patient falls
in categories with markedly different survival expecta-
tions. Retrospective classification of our patient revealed
that at the time of SMF diagnosis she was at intermediate-
2 risk according to MYSEC-PM, and at intermediate-1
risk according to DIPSS, with a projected survival of 4.5
and 14.1 years, respectively. This kind of discrepancy
between risk models may occur in up to 50% of patients
with SMF [24] and poses a significant challenge in
transplant indication, since EBMT/ELN recommendations
suggest that HSCT should be offered only to eligible
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patients whose survival is expected to be <5 years [13]. In
such cases, we believe that information from MYSEC-
PM, the only scoring system specifically developed for
SMF, should outweigh the risk assessment obtained from
IPSS, DIPPS, DIPSS-plus or MIPSS70, which were
developed in patients with PMF and are less accurate in
discriminating different prognostic groups in SMF
patients [25, 26]. Moreover, we have to bear in mind that
all the presently available prognostic scores have been
built on cohorts of patients who were not exposed to novel
drugs such as ruxolitinib, and the weight of treatment-
related clinical changes on single prognostic variables
compared to MF-related changes is unclear. For example,
many patients on ruxolitinib develop anemia (+2 points
according to the DIPSS prognostic model) but ameliorate
systemic symptoms (−1 point), therefore potentially
changing several times over months their prognostic
group. Altogether, these considerations reflect the uncer-
tainty about prognostic scores alone in defining transplant
indication. In this regard, it should be underlined that the
predictive efficacy of MYSEC-PM score in ruxolitinib-
treated patients has been validated in a retrospective study
[24] and that two recent reports from the EBMT and the
Spanish registry confirmed the efficacy of MYSEC-PM,
as well as its superiority over DIPSS or IPSS scores, in
predicting posttransplant survival [27, 28]. Of note, about
60% of patients in both these series belonged to the low or
intermediate-1 MYSEC-PM risk group, and downgrading
from higher IPSS categories was mainly related to the
large effect of age in the MYSEC-PM model: in fact, only
a minority of patients in a transplant age (i.e., <70 years)
are categorized in intermediate-2 or high MYSEC-PM
risk. This large contribution of age to the scoring system
may thus decrease its sensitivity to the other disease-
related adverse risk factors (e.g., circulating blasts), which
could be important for transplant decisions [28].
Risk factors for survival after transplant comprise high
transfusion requirement, massive splenomegaly, non-
sibling donor type [29], advanced age, JAK2 V617F-
mutated status, constitutional symptoms [10], and HLA-
mismatched donor [11]. Of note, patients in these studies
were quite heterogeneous and no unifying prognostic
variables can be identified, except for age (>55–57 years).
Recently, a new Myelofibrosis Transplant Scoring System
(MTSS) was proposed to predict survival after HSCT on
the basis of the following clinical and molecular variables:
leukocytes >25 × 109/L, platelets <150 × 109/L, Karnofsky
scale <90%, age >57 years, ASXL1 mutation (1 point
each), JAK2-mutated or triple negative status (2 points),
and mismatched unrelated donor (2 points) [27].
According to these variables, patients were stratified in
low (score 0–2), intermediate (score 3–4), high (score 5),
and very high (score >5) risk groups with a 5-year sur-
vival estimation of 83%, 64%, 37%, and 22%,
respectively.
Prognostic scores: key points
• New scoring systems have been recently developed for
PMF (MIPSS70) and SMF (MYSEC-PM) prognostica-
tion, and for transplant outcome (MTTS).
• Still, IPSS and DIPSS are widely used in clinical practice
and for the transplant-decision process, although the
MYSEC-PM score has been proved to be more accurate in
SMF patients.
• Impact of subclonal mutations in SMF deserves
confirmation.
• The weight of prognostic variables in patients treated with
JAK inhibitors has not been still assessed prospectively.
Besides these prognostic scores, a further element of
uncertainty is how to consider the response to ruxolitinib
or other JAK inhibitors. It is possible that patients who do
not respond to ruxolitinib, even after dose optimization,
should be referred early for HSCT. In fact, non-
responsiveness to ruxolitinib could eventually be con-
sidered as a major selection criterion for referral to HSCT,
although more studies are needed to determine the timing
at which HSCT should be considered in a non-responsive
patient. In a small cohort of patients (n= 22) briefly
exposed to ruxolitinib before planned HSCT (median
treatment duration 97 days, range 20–316), 1-year OS was
superior for patients with spleen response to ruxolitinib
than for patients who failed or lost their response [30]. In
addition, a larger study on 100 patients treated with JAK
inhibitors (ruxolitinib 90%, others 10%) showed that 2-
year OS ranged from 91% for patients experiencing
clinical improvement to 32% for those developing leu-
kemic transformation on treatment with JAK inhibitors;
patients with stable disease or transient response had an
intermediate prognosis [21]. If a favorable response to
JAK inhibitors leads to a better transplant outcome
because patients who respond to JAK inhibitors have an
intrinsic more favorable biology or because JAK inhibi-
tors ameliorate the clinical status of patients remains an
unanswered question.
Finally, we recently reported on a large multicenter
cohort of patients treated with ruxolitinib in real life (40%
aged <65 years), showing that 18 and 22% of cases were
treated for >12 months even with unstable or no spleen
response, respectively [31], reflecting a common tendency
to use ruxolitinib in clinical practice as a strategy to delay
HSCT rather than a bridge to it.
M. Tiribelli et al.
Pretransplant ruxolitinib: key points
• Response to ruxolitinib is associated with favorable
outcomes after HSCT.
• Patients failing ruxolitinib therapy should be considered as
candidates for HSCT within 6–12 months, if suitable.
Transplant and posttransplant evaluation:
realization, management and outcome
According to the revised 2018 ELN recommendations [32],
patients with intermediate-1 risk disease should be con-
sidered as eligible for HSCT in the presence of detrimental
prognostic factors, such as adverse cytogenetics or muta-
tions [33–36], high need for transfusions [37], or >2% of
circulating blasts [38]. All these conditions were met in the
present case, except for the lack of information about
molecular status when we decided to candidate the patient
to HSCT. Prior to HSCT we documented grade 3 fibrosis
and osteosclerosis at bone marrow reevaluation, and muta-
tional analysis of the CALR gene revealed a type 2 muta-
tion. This is of interest as patients with mutations in the
CALR gene appear to have better overall survival [4] and
better posttransplant outcomes [39, 40], even though the
prognostic significance of type 2/type 2-like CALR muta-
tions seems to be less favorable than type 1/type 1-like
mutations [35, 41]. Furthermore, during the pre-
transplantation waiting period, the patient’s DIPSS score
had raised to 5, and she was thus considered as high risk.
Iron overload is common in MF due to the high
requirement for transfusions and the disease-associated
inflammatory state; moreover, MF patients have been
shown to have higher levels of hepcidin than normal con-
trols, and increased levels of hepcidin and ferritin appear to
be a DIPSS-plus-independent adverse prognostic factor for
survival [42]. Iron chelation with deferasirox was associated
to erythroid improvement and reduction or abolition of
transfusion dependence in 15–40% of MF patients [43, 44].
Due to the adverse effects of iron overload on HSCT out-
comes [45], evaluation of pretransplant iron status is
recommended and treatment with deferasirox may be ben-
eficial in terms of posttransplant engraftment and long-term
outcomes [46, 47].
Splenomegaly negatively affects HSCT outcomes as it
may be associated with poor graft function and increased
mortality [48]. Despite these observations, it remains
uncertain if splenectomy prior to transplantation is asso-
ciated with improved outcomes. At present, there is some
evidence to support pretransplant splenectomy [49–51], but
postoperative complications, present in around one-half of
all patients [52], could lead to delays in HSCT. Therefore, it
is accepted that clinical decisions on surgical reduction of
spleen size should be made on an individualized basis [19].
In the present case, pre-HSCT splenectomy was not taken
into consideration given the presence of clinically sig-
nificant portal and splenic vein thrombosis, necessitating
administration of heparin, and transfusion-dependent
anemia.
There is general agreement that, as for other diseases, an
HLA-matched donor, either sibling or unrelated, is asso-
ciated with superior overall survival [27, 53], although
some experiences found a worse outcome in MF patients
transplanted from an unrelated donor, regardless of HLA-
matching status [54]. However, there is increasing evidence
about the use of alternative donors. Raj et al. reported on 56
MF patients transplanted between 2009 and 2015 from a
family mismatched donor (i.e., relatives with ≥2 Ag HLA
different from recipient), with a 2-year overall survival rate
of 56% but a rather high non-relapse mortality (NRM) of
38% at 2 years [55]. In a recent retrospective review, NRM
and 4-year OS rates were similar in patients receiving their
first transplant from HLA-matched related donor peripheral
blood stem cells or from HLA-MUD bone marrow, while
long-term survival was inferior in patients transplanted from
umbilical cord blood, partly due to higher NRM [56].
Information about haploidentical related donor in MF is still
scarce; in a comparison between HLA-identical sibling and
“alternative” donors, including 20 haploidentical, trans-
planted in the years 2011–2014, Bregante et al. found
similar survival rates in the two cohorts (72% and 69%,
respectively) [57].
With regards to the conditioning regimen, there are limited
data on the choice of the optimal regimen give the lack of
prospective clinical trials comparing MAC to RIC in MF [58].
However, retrospective studies in the pre-ruxolitinib era have
reported that ideal candidates for MAC are younger patients
(<40 years old), without comorbidities and with HLA-
identical sibling donor [59], while RIC may be preferred in
patients older than 50 years [4, 58, 60]. Accordingly, RIC
with fludarabine+ thiotepa was adopted in the present case.
A recent prospective randomized study compared fludarabine
in combination with busulfan or thiotepa as conditioning
regimen in 60 patients undergoing HSCT for MF, showing
comparable clinical outcome in the two arms [51]. However,
other available data are somewhat discrepant on the outcomes
of patients undergoing fludarabine-melphalan based RIC
regimens [54, 61]. Recently, Gupta et al. reported a pro-
spective trial of ruxolitinib treatment followed by a RIC
regimen: the cumulative incidences of graft failure, NRM,
acute GvHD, and chronic GvHD at 24 months were 16%,
28%, 64%, and 76%, respectively; 2-year overall survival was
61 and 70% for patients receiving transplant from related or
unrelated donor, respectively. The role of pretransplant rux-
olitinib is also supported by a retrospective study of 159 MF
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patients receiving (29%) or not receiving ruxolitinib (71%) at
any time before HSCT: graft failure, time to engraftment, and
NRM were similar, while a trend for lower risk of relapse was
seen in the ruxolitinib group [62]. Moreover, there was no
difference in any outcome variable between those who
responded to ruxolitinib and those who failed or lost response
to the drug [62]. Another aspect that remains unclear is the
rate and schedule for pretransplantation discontinuation of
ruxolitinib. In our case, ruxolitinib was quickly tapered
downward at 1 week prior to HCT and stopped the day
before starting the conditioning regimen. This decision was
largely made upon empirical considerations and on the
observation that following interruption or discontinuation of
ruxolitinib symptoms of MF may return over a period of
~1week [63]. Some studies have suggested that ruxolitinib
should be continued near to the start of conditioning therapy
[30, 53, 60], while a recent experience reported the safety of
continuing low-dose ruxolitinib (5 mg BID) until stable
engraftment in 12 MF patients undergoing allogeneic trans-
plant [64]. Drug discontinuation symptoms were reported to
be more common in patients who had a longer interval
between last dose of a JAK1/2 inhibitor and beginning of the
conditioning regimen, with 29% of patients developing
symptoms with an interval ≥6 days compared with only 7%
among those with an interval <6 days [53]. Moreover, the
possible appearance of significant clinical events related to
discontinuation of ruxolitinib may occur, which may even
lead to delay in HSCT [53].
Transplant procedure: key points
• HLA-matched sibling or unrelated donor is the preferable
choice, but there is increasing evidence of feasibility of
HSCT form alternative donors.
• Patients older than 50 years should receive a RIC
transplant.
• The conditioning regimen is based on fludarabine
combined with either busulfan, thiotepa or melphalan.
Patients receiving pretransplant ruxolitinib should be
tapered and discontinued just before starting the condi-
tioning regimen to avoid a cytokine rebound.
Lastly, the role of ruxolitinib post HSCT remains unclear
and there is very limited information to guide clinicians.
The presence of minimal residual disease (MRD) or overt
relapse after HSCT pose a significant clinical challenge, and
MF recurrence remains the main cause of death in the long
term, as has been recently demonstrated in a large retro-
spective analysis on over 1000 patients with MF trans-
planted between 1995 and 2014 in Europe [65]. Detection
of posttransplant relapse may be challenging, as bone
marrow fibrosis may persist for months after HSCT [66]
and molecular monitoring is not yet standardized. While
detection of JAK2 mutations after transplant has been found
to predict MF relapse [67], no data are available on the role
of CALR, MPL or monitoring other molecular markers and
their role in guiding therapy. In view of the lack of uniform
criteria, we propose serial monitoring (e.g., at 3, 6, and
12 months after HSCT) of bone marrow biopsy and driver
mutations present in individual MF patients.
In patients relapsing after transplant, discontinuation of
immunosuppressive drugs, administration of donor lym-
phocyte infusion (DLI), chemotherapy, and second allo-
geneic transplant has been proposed [68]. Response to DLI
seems to be more effective in patients with recurrence of
MRD and monitored by JAK2 mutation levels in peripheral
blood than in patients with full clinical relapse [69]. A
role of JAK inhibitors in this setting appears reasonable, but
still scarcely defined [70]. More recently, ruxolitinib has
also emerged as an option for treating steroid-resistant
acute and chronic GVHD [71], and promising results
have been reported in a small group of MF patients who
were treated with low-dose ruxolitinib until stable engraft-
ment [64].
Posttransplant management: key points
• Albeit the limited experience, there seems to be a role for
ruxolitinib in the peri- and posttransplant period.
• Optimal histological and molecular monitoring of MF
after HSCT is still to be defined.
Conclusion
HSCT remains the main curative option for MF patients
even in the era of JAK inhibitors. Eligibility for transplant
should rely on the integrated evaluation of disease- and
transplant-related risk factors, particularly in older adults. A
thorough mutational analysis covering driver and subclonal
mutations may help to define indication for HSCT in lower-
risk fit patients. RIC nowadays represents the most common
type of HSCT in MF, and busulfan or thiotepa plus flu-
darabine are both appropriate conditioning regimens.
Response to ruxolitinib as a “bridge to transplant” can be
obtained in about 30–50% of patients and predicts a
favorable outcome after HSCT.
Some of the most pressing issues to be studied in
future prospective clinical trials involve the place and
duration of JAK inhibitors in the pretransplant period
(together with an optimized timing sequence for dis-
continuation), early versus late transplantation, and the role
of ruxolitinib or other drugs in managing patients in the
posttransplant period.
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